Novo Nordisk has multiple, strong upcoming, positive catalysts, related to its GLP-1 weight-loss drugs, Ozempic and Wegovy.

The release of early-stage data on three oral weight loss drug candidates hints at which companies have the strongest hand, ...

GE HealthCare’s recently acquired MIM Software division has secured an FDA clearance for a tool to help quantify the density ...

Real-world data showed reductions in healthcare resource utilization and improved glycemic control over 1 year with ...

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 584.52% and ...

Swiss pharmaceutical giant Novartis said Wednesday that it does not plan to enter into the “frenzy” of weight loss drugs.

The weight-loss market is heating up as a number of companies are looking for a way to upend the dominance of market leaders Novo Nordisk ( NVO) and Eli Lilly ( LLY) by introducing GLP-1 pills.

He started working at Danville Plumbing and Heating before building a career at Eli Lilly and Company working his way up from a janitorial position to Supervisor of Capsule Machine Maintenance before ...

In recent years, the company has primarily stuck to rights deals with major pharmas to bolster its offerings. Organon signed a deal with Eli Lilly for European rights to the pharma’s migraine meds ...

Jim Cramer warned that if the housing market rally keeps going, it might lead to a sell-off if the Federal Reserve announces ...

The demand for medications like Ozempic continues to cause shortages for both those seeking weight loss and patients with ...

According to Benzinga Pro, Eli Lilly's peer group average for short interest as a percentage of float is 4.49%, which means ...